论文部分内容阅读
据近期出版的《柳叶刀》杂志报道,研究人员通过对肥胖人群的随机对照试验发现,Rimonabant不但能减轻患者的体重,而且还能降低心血管疾病(CVD)的发病风险。来自于比利时安特卫普医学院的 Luc Van Gaal博士报道说,使用 Rimonabant 治疗一年以上的患者可出现持续的且有临床意义的体重降低和腰围缩小,并可使有关心血管和代谢性疾病的发病风险得以改善。动物实验证实,大麻甙-1受体(CB1)
According to a recently published issue of The Lancet, researchers found that randomized controlled trials of obese people found that Rimonabant not only reduced patients’ weight but also reduced the risk of developing cardiovascular disease (CVD). Dr. Luc Van Gaal from the Antwerp School of Medicine in Belgium reported that patients treated with Rimonabant for more than a year had sustained and clinically significant weight loss and narrowing of the waist and were at increased risk of developing cardiovascular and metabolic diseases Be improved. Animal experiments confirmed that cannabinoid -1 receptor (CB1)